+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Spine Biologics Market Size was valued at USD 2.6 Billion in 2022. The Spine Biologics market industry is projected to grow from USD 2.8 Billion in 2023 to USD 4.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.45% during the forecast period (2023 - 2032). An increase in the number of elderly persons and the incidence of spinal anomalies, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYERDatabase and Analyst Review
The aging population, an increase in the frequency of spinal deformities, and technological advancements in bone grafting techniques are the main factors driving the global market. The market is also growing as more people choose minimally invasive procedures and as degenerative spine disorders are becoming more common. Additionally, the two state-of-the-art biological approaches most frequently employed by surgeons worldwide to repair spinal abnormalities are interbody fusion and direct lateral interbody fusion.
The ideal way for treating spinal problems is the use of lateral body fusion, a minimally invasive procedure that makes advantage of recent developments in biomaterials. It causes fewer complications and enables a speedy and safe recovery. It further raises the demand for spine biologics in the management of disc formation, sclerosis, and other spine-related disorders. Globally, the aging population is growing, which will raise demand for problem detection and treatment. People over 50 are more prone to suffer from spinal abnormalities or structural changes, which makes spinal injuries among them more common. Therefore, during the anticipated timeframe, the aforementioned factors will dominate the market for spine biologics. The increase in incidence of degenerative spine illnesses and the sharp increase in treatment rates globally are the main factors driving the growth of the spine biologics market.
Due to technological advancements in bone grafting techniques, the importance of these biologics in spine surgery, and the rising demand for minimally invasive procedures, the market for spine biologics is expanding significantly. The spine biologics industry has been significantly impacted by the increased acceptance of biomaterials due to their quick healing, quick recovery times, ability to stimulate cellular growth, high utilization in the treatment of degenerative disc disorders, spinal cord injuries, and bone fusion procedures. The aging population's expansion, increased awareness of recently developed spine therapy options, research and development initiatives, and an increase in healthcare spending are further factors that favorably affect the market for spine biologics. Thus, driving the Spine Biologics market revenue.
The global Spine Biologics market segmentation, based on Product includes bone allografts, bone graft substitute, platelet rich plasma, and bone marrow aspirate therapy. Due to their numerous benefits, bone allografts dominated the market overall in 2022. Allografts are being used more frequently than autografts due to their advantages in terms of osteoconductivity and quick structural support. Additionally, because no second surgery is required to retrieve the bone, allografts reduce surgical time and hasten the healing of wounds. Bones for natural transplants are extracted from the patient's or a donor's body. Companies like Zimmer Biomet offer natural bone grafts (xenografts).
The global Spine Biologics market segmentation, based on Surgery Type, includes anterior cervical discectomy and fusion (ACDF), transforamenal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), and lateral lumbar interbody fusion (LLIF). The transforaminal lumbar interbody fusion (TLIF) and ACDF segments both made considerable contributions to the global spine biologics market in 2022. Surgery is a safe and effective treatment for nerve root or spinal cord compression, with very rare and manageable side effects. In order to stabilize the injured vertebrae and release pressure from the spinal cord and nerve roots in the cervical spine, this specific type of neck surgery involves the removal of a damaged disc followed by intervertebral fusion. The surge in cervical cancer cases is leading to market growth.
The global Spine Biologics market segmentation, based on End User, includes hospitals, spinal surgery centers, orthopedic clinics, and others. The hospital sector had the largest revenue share in 2022, and it is anticipated that this trend would continue for the duration of the forecast. The primary driver of the market is an increase in the number of spine fusion surgeries performed in these facilities. However, due to high hospitalization costs, hospital admissions have recently decreased while outpatient visits have climbed. This will undoubtedly put the use of spine biologics in hospital settings in peril during the next years.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYERDatabase and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The highest market share (45.80%) for spine biologics worldwide belongs to North America. The rise in prevalence of spine ailments like spinal stenosis, disc-related problems, and spondylolisthesis as well as sustained economic growth are all factors contributing to the market's expansion. The National Spinal Cord Injury Statistical Center estimates that in 2017, there were around 285,000 spinal cord injuries reported in the United States. Further, In the North American area, the U.S. Spine Biologics market had the biggest market share, while the Canada Spine Biologics market had the quickest rate of expansion.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYERDatabase and Analyst Review
The market for European spinal biologics is predicted to grow positively over the forecast period. Technology developments, an increase in hospitals, and an expanding patient base for spine biologics are the main factors driving this market's expansion. Further, In the European region, the German Spine Biologics market had the biggest market share, and the U.K. Spine Biologics market had the quickest rate of growth.
Due to a large patient population and greater awareness of the benefits of biologics among patients and surgeons, the Asia-Pacific Spine Biologics market is anticipated to grow at the quickest CAGR from 2023 to 2032. A number of variables, including the region's improving infrastructure and healthcare facilities, rising healthcare expenditures, and the high prevalence of spine injuries, particularly those brought on by traffic accidents, are driving the regional market. Due to inactive lives and changing living choices, the prevalence of obesity has increased, and this trend is projected to continue to drive the sector going forward. Further, In the Asia-Pacific region, the Indian Spine Biologics market had the quickest rate of growth while China's Spine Biologics market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Spine Biologics market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Spine Biologics sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Spine Biologics industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Spine Biologics sector. Major players in the Spine Biologics market, including Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC, are attempting to increase market demand by investing in research and development operations.
RTI Surgical (RTI) is a significant international private-label OEM that provides comprehensive services for product development and life cycle management to benefit both patients and leading medical technology companies. Utilizing our knowledge of tissue and biologics, we provide partners in a variety of market sectors, including but not limited to dental, plastic and reconstructive surgery, sports medicine, spine, trauma, and urology/urogynecology. In accordance with an agreement they made in August 2018, Aziyo Biologics provided RTI Surgical Holdings, Inc. with ViBone, a bone repair product with autograft capabilities, for use in a variety of orthopedic procedures.
Orthofix Medical Inc. (Orthofix), a producer of medical equipment, formerly known as Orthofix International NV, provides reconstructive and regenerative musculoskeletal solutions to medical professionals everywhere. The company's major products include those for managing fractures, regenerative goods and tissue forms, child and limb reconstruction, motion preservation and fixation implant devices, and foot and ankle products. Orthofix offers its products both directly and through a network of distributors in order to reach hospitals, physicians, integrated health delivery systems, ambulatory surgery centers, and other purchasing groups across the world. It also has facilities there, in addition to the US, UK, Brazil, Italy, France, and Germany. Based in Lewisville, Texas, Orthofix is a company with US operations. In October 2022, Orthofix, a global medical device firm, and SeaSpine, a global medical technology company, agreed into a binding merger agreement to form a premier spine and orthopedic corporation with a focus on orthopedics and spine surgery. The united entity would develop into a top surgical navigation system with the addition of highly complementary biologics.
· Arthrex, Inc.
· Cesca Therapeutics Inc.
· DePuy Synthes
· Orthopaedic Seminar
· Exactech, Inc.
· K2M, Inc.
· Lattice Biologics Ltd
· Medtronic
· NuTech Spine, Inc.
· NuVasive Inc.
· Orthofix Holdings, Inc.
· Regen Lab USA LLC
· RTI Surgical Holdings, Inc.
· Stryker
· Wright Medical Group N.V.
· XTANT MEDICAL
· Zimmer Biomet
· Smith & Nephew
· Dr PRP USA LLC
In October 2022: The first patient to get invasive spinal colon surgery in Japan had treatment at the International University of Health and Wellness at Mita Hospital in Tokyo using Royal Philips' Augmented Reality (A.R.) surgical navigation tool, ClarifEye, emphasizing the successful post-operative outcomes.
In February 2020: The SeaSpine holding firm joined forces strategically with 7DSurgical Inc. to concentrate on surgical treatments for spinal ailments.
In May 2020: The Modulus XLIF Dual-sided plate was introduced by NuVasive, a pioneer in spine technology, and was given 510(k) clearance by the US Food and Drug Administration.
In August 2018: Aziyo Biologics was in agreement with RTI Surgical Holding Inc. In accordance with the agreement, Aziyo Company provides RTI Surgical with assistance for its ViBone device, which is used to mend bone during auto-graft procedures for various orthopedic surgeries.
· Bone Allografts
· Bone Graft Substitute
· Platelet Rich Plasma
· Bone Marrow Aspirate Therapy
· Anterior Cervical Discectomy and Fusion (ACDF)
· Transforamenal Lumbar Interbody Fusion (TLIF)
· Anterior Lumbar Interbody Fusion (ALIF)
· Lateral Lumbar Interbody Fusion (LLIF)
· Hospitals
· Spinal Surgery Centers
· Orthopedic Clinics,
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 2.6 Billion |
|
Market Size 2023 |
USD 2.8 Billion |
|
Market Size 2032 |
USD 4.6 Billion |
|
Compound Annual Growth Rate (CAGR) |
4.45% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Product, Surgery Type, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC |
|
Key Market Opportunities |
Technological advancements |
|
Key Market Dynamics |
Growing geriatric population and rising prevalence of spine deformities |
The global Spine Biologics Market was valued at USD 2.6 billion in 2022, and it is estimated to reach USD 4.6 billion by 2032.
The global market is projected to grow at a CAGR of 4.45% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC.
The Bone Allografts Product dominated the market in 2022.
The Anterior Cervical Discectomy and Fusion (ACDF) Surgery Type had the largest share in the global market.
Report Code :
RL65138
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst